Last reviewed · How we verify
Pediarix TM, Infanrix penta TM
Pediarix and Infanrix penta are combination vaccines that stimulate the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B through inactivated antigens.
Pediarix and Infanrix penta are combination vaccines that stimulate the immune system to produce antibodies against diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B through inactivated antigens. Used for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B in infants and children.
At a glance
| Generic name | Pediarix TM, Infanrix penta TM |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Combination vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease Prevention |
| Phase | Phase 3 |
Mechanism of action
These vaccines contain inactivated or recombinant antigens from multiple pathogens that trigger both humoral and cellular immune responses, leading to the production of protective antibodies and memory immune cells. Upon exposure to the actual pathogens, the primed immune system rapidly recognizes and neutralizes them, preventing infection or severe disease.
Approved indications
- Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and hepatitis B in infants and children
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
- Loss of appetite
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pediarix TM, Infanrix penta TM CI brief — competitive landscape report
- Pediarix TM, Infanrix penta TM updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI